Showing 4031-4040 of 9578 results for "".
- Delgocitinib for CHE Gains EC Approval, FDA NDA Acceptancehttps://practicaldermatology.com/news/delgocitinib-che-gains-ec-approval-fda-nda-acceptance/2468259/Delgocitinib cream 20 mg/g (2%) reached major milestones in both the United States and Europe, LEO Pharma Inc. announced. The US Food and Drug Administration (FDA) accepted a filing for a New Drug Application (NDA) for LEO Pharma’s AnzupgoÒ for the treatment of adults with moderate-to-seve
- Almirall to Present New Drug Data at EADVhttps://practicaldermatology.com/news/almirall-present-new-drug-data-eadv/2468258/Almirall will present 34 abstracts detailing the latest research on lebrikizumab for moderate-to-severe atopic dermatitis in adolescents and adults and tildrakizumab and Almirall’s CAL/BDP cream for moderate-to-severe plaque psoriasis in adults at the 33rd Congress of the European Academy of Derm
- EADV Presentation to Highlight New IL-13/IL-31 Bispecific Antibodyhttps://practicaldermatology.com/news/eadv-presentation-highlight-new-il-13il-31-bispecific-antibody/2468228/Data from a preclinical study of ZL-1503, an IL-13/IL-31 bispecific antibody for the treatment of atopic dermatitis (AD), will be presented in a late-breaking oral presentation at the European Academy of Dermatology and Venerology Congress (EADV) 2024 taking place September 25-28 in Amsterdam, Ne
- ASDS Hosts New 'Expertise Summit'https://practicaldermatology.com/news/asds-hosts-new-expertise-summit/2468191/More than 50 dermatologic surgeons and dermatology residents gathered in Chicago, Illinois, on September 7-8 for a new course from the American Society for Dermatologic Surgery (ASDS), titled “ASDS Expertise Summit: Surgery. Injectables.” Practical Dermatology Editorial Board member Dr. As
- Long-Term Roflumilast Cream Shows Sustained Efficacy in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/long-term-roflumilast-cream-shows-sustained-efficacy-pediatric-atopic-dermatitis/2468063/A recent open-label extension study showed more than 70% of pediatric patients aged 2-5 years treated with roflumilast cream 0.05% achieved EASI-75 after 56 weeks of treatment, with sustained efficacy and favorable safety in managing atopic dermatitis (AD). The
- Study Explores Potential of GLP-1 Agonists for Skin Disease Managementhttps://practicaldermatology.com/news/study-explores-potential-glp-1-agonists-skin-disease-management/2468016/Recent research highlights the potential of GLP-1 agonists in managing dermatological conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease, especially in patients with obesity or type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 (G
- European Commission Approves Celltrion’s Stelara Biosimilar SteQeymahttps://practicaldermatology.com/news/european-commission-approves-celltrions-stelara-biosimilar-steqeyma/2467952/Celltrion announced that the European Commission (EC) has approved SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases, including psoriasis. The EC's approval follows a positive opinion from the Committee for Medici
- Higher BMI in Early Childhood Linked with Increased Atopic Dermatitis Riskhttps://practicaldermatology.com/news/higher-bmi-early-childhood-linked-increased-atopic-dermatitis-risk/2467912/New research indicates that a higher body mass index (BMI) in early childhood is associated with an increased risk of developing immune-mediated skin diseases (IMSDs) such as atopic dermatitis (AD), alopecia areata (AA), and psoriasis. The research team looked at data on over 2 million chi
- Annual Science of Skin Event Highlights Empowering Conversations About Chronic Diseaseshttps://practicaldermatology.com/news/annual-science-skin-event-highlights-empowering-conversations-about-chronic-diseases/2467751/Empowering conversations around chronic skin diseases is something AbbVie aims to normalize. The fourth annual Science of Skin event featured a panel of experts and patients who shared insights on managing chronic skin conditions and improving quality of life, and Practical Dermatology was there.
- European Committee Recommends Approval of Delgocitinib for CHEhttps://practicaldermatology.com/news/european-committee-recommends-approval-delgocitinib-che/2467631/The European Medicine Agency Committee for Medicinal Products for Human Use (CHMP) has “adopted a positive opinion that recommends the approval” of delgocitinib cream for the treatment of adult patients with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequ